Study of erythrocytes as a novel drug carrier for the delivery of artemether by Riaz, Muhammad Ijaz et al.
Braz. J. Pharm. Sci. 2019;55:e17680 Page 1 / 7
Brazilian Journal of 
Pharmaceutical Sciences
http://dx.doi.org/10.1590/s2175-97902019000117680
O
rig
in
al
A
rt
ic
le
*Correspondence: M. F. Sohail. Riphah Institute of Pharmaceutical Sciences, 
Riphah International University Lahore Campus, Lahore, Pakistan. Phone: +92 
344 4120001. E-mail: farmacist.pk@gmail.com 
G. Shahnaz. Department of Pharmacy, Faculty of Biological Sciences, Quaid-
i-Azam University, Islamabad, Pakistan. Phone: +92 51 90644137. E-mail: 
gshahnaz@qau.edu.pk 
Study of erythrocytes as a novel drug carrier for the delivery of 
artemether
Muhammad Ijaz Riaz1, Hafiz Shoaib Sarwar1,2, Mubashir Rehman3, Umar Farooq Gohar1,6, Syed 
Atif Raza4, Muhammad Irfan Siddique5, Gul Shahnaz2*, Muhammad Farhan Sohail1,2*
1Riphah Institute of Pharmaceutical Sciences, Riphah International University Lahore Campus, Lahore, Pakistan, 2Department 
of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan, 3Faculty of Pharmacy, University 
of Central Punjab, Lahore, Pakistan, 4University College of Pharmacy, University of the Punjab, Allama Iqbal Campus, 
Lahore, Pakistan, 5Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan, 
6Department of Industrial Biotechnology, Government College University, Lahore, Pakistan
Resealed erythrocytes have been explored in various dimensions of drug delivery, owing to their high 
biocompatibility and inability to initiate immune response. The present research was designed to evaluate 
the drug delivery potential of erythrocytes by loading a hydrophobic anti-malarial drug, Artemether. Three 
different loading techniques were applied to achieve maximum optimized drug loading. A HPLC method 
was validated for drug quantification in erythrocytes. The relatively high loading was achieved using 
hypotonic treatment was 31.39% as compared to other two methods. These, drug loaded erythrocytes 
were characterized for membrane integrity via ESR showing higher ESR values for drug loaded cells 
as compared to normal cells. Moreover, microscopic evaluation was done to observe morphological 
changes in erythrocytes after successful loading which showed swollen cells with slight rough surface 
as compared to smooth surface of normal cells. Drug release was studied for 8 h which showed more 
than 80% release within 3-7 h from erythrocytes treated with different hypotonic methods. Overall, the 
study revealed a potential application of erythrocytes in delivery of hydrophobic drugs using hypotonic 
treatment as compared to other methods. 
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INTRODUCTION
According to the world health organization (WHO) 
malaria occupies the first place in parasitic diseases that 
can kill the people worldwide. An estimated 500 million 
cases are reported annually with 1-2.5 million deaths 
out of which majority of children under five years of 
age (Organization, 2015). It is caused by the parasites 
of genus Plasmodium belonging to species Plasmodium 
vivax, P. ovale, P. malariae, P. falciparum. While taking 
the blood meal the female anopheles mosquito transmits 
the sporozoites of plasmodium parasites into the blood of 
the host. Sporozoites reach the blood within short period 
of time Within a short period of time the sporozoites 
reaches the blood and are transported to the liver where 
they converted to merozoites, enter blood circulation 
and invade RBCs. Within RBCs these are multiplied 
via asexual reproduction and infect other RBCs, thus 
disseminating the infection (Matteelli et al., 1997). 
Currently, there is no approved malaria vaccine 
available in market and as the currently available RTS,S/
AS01 vaccine has shown less than 50% efficacy, thus, 
is not recommended by WHO (Gosling et al., 2016). 
Therefore, the treatment of malaria relies mainly on 
the use of chemotherapeutic agents. Quinine was the 
first drug used to treat malaria which later became less 
effective leading to the discovery and development of 
new antimalarial drugs. In 1940s, a German scientist 
synthesized chloroquine, an effective alternative of 
quinine which showed remarkable effectiveness during 
World War II (Renslo, 2013). High therapeutic doses of 
chloroquine are required because of greater trapping into iD
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kidneys, liver, lung and spleen. In turn, use in higher doses 
for about 3-6 years may results in renal toxicity. In turn, the 
higher doses may result in toxicity such as retinal toxicity 
after using for 3-6 years (L’Estrange, 1987). A number of 
new molecules have been developed to treat malaria better 
than quinine and chloroquine. Artemether (ARM) is one 
of those anti-malarial drugs that inhibits P. falciparum 
encoded sarcoplasmic-endoplasmic reticulum calcium 
ATPase and clear parasitaemias better than chloroquine 
(Flannery, Chatterjee, Winzeler, 2013). Artemether is 
also reported to reduce gametocytogenesis by acting on 
the ring stages in early stages of gametocytes. Artemether 
is mainly metabolized by CYP450 2B6, CYP450 3A4 
and possibly CYP450 2A6. The drug is extensively and 
rapidly metabolized into dihydroartemisinic that is the 
main active metabolite. However, a very short half-life, 
lack of oral absorption and poor aqueous solubility limits 
is use (Karbwang et al., 1997). Currently, an oil-based 
injectable formulation for intramuscular administration 
is available commercially. However, its use is limited 
due to its non-defined and erratic absorption. So, there 
is need of developing a suitable drug delivery system for 
the intravenous delivery of ARM (Bhadra, Bhadra, Jain, 
2005).
Novel drug delivery systems (NDDS) are amongst 
the widely explored delivery systems to overcome various 
limitations faced by the conventional drug delivery 
systems. Various NDDS including liposomes, niosomes, 
polymeric and metallic nanoparticles, dendrimers and 
many others are reported with some good potential in 
drug delivery. Some of these NDDS have been approved 
by FDA and a lot more are in process of approval (Hassan 
et al., 2017). In this scenario, drug loaded erythrocytes or 
resealed erythrocytes have been reported as a promising 
delivery system for drugs and various enzymes (Tyrrell, 
Ryman, 1976). The most important benefits they present 
is the biocompatibility and biodegradation with long 
circulating half-life and can be loaded with numerous 
biological agents. Resealed erythrocytes can easily be 
prepared by obtaining blood from various organisms and 
erythrocytes are separated using many techniques. These 
erythrocytes are then treated with different processes 
to load various biological agents and injecting back to 
the same organism. Upon injection of the drug loaded 
erythrocytes, they act as slow drug releasing depot and 
target reticulo-endothelial system (RES) and prevent the 
enzymatic degradation (Gothoskar, 2004). To control the 
dissemination of malaria the drug delivery via RBCs can 
be of promising strategy as the newly released merozoites 
will also attack the drug loaded RBCs along with normal 
RBCs where they encounter the high concentration of 
therapeutic agents, thus providing a suitable control of 
malarial infection. 
This study was designed to develop and in vitro 
characterize ARM loaded erythrocytes as an efficient 
carrier. Hypotonic treatment is reported as an efficient 
method for drug loading with less effects on RBCs. Three 
different techniques based on hypotonic treatment were 
applied to check the effect on loading efficiency, ESR and 
drug release from RBCs to develop an optimized delivery 
system.
MATERIAL AND METHODS
Material
Sodium chloride, Giemsa, sodium hydroxide 
and potassium dihydrogen phosphate were purchased 
from Sigma-Aldrich (Germany). Water, methanol and 
acetonitrile were of HPLC grade. Artemether was received 
as a gift from NovaMed Pharmaceuticals (Pvt.) Ltd, 
Lahore Pakistan.
Methods
Erythrocytes isolation
Fresh human blood was withdrawn via vein puncture 
with volunteer’s consent and stored at 4oC using the 
reported method (Sohail et al., 2017). The erythrocytes 
were separated from blood by centrifugation at 1000 rpm 
for 20 min. The pellet containing RBCs was collected and 
washed with phosphate buffer solution (pH 7.4). These 
isolated RBCs were used for the preparation of resealed 
erythrocytes using different methods of drug loading.
Drug loading techniques
Three different drug loading methods were applied 
to study the effect of process variables on achieving 
maximum loading of ARM along with RBCs membrane 
integrity to control the drug release from loaded RBCs. 
The detailed procedures are described below. 
Method A (Hypotonic dilution) 
A volume of 8 mL of washed erythrocytes was taken 
in the test tube and 10 mL of the 4% ARM solution in 
acetonitrile and water was added. The tonicity of the drug 
solution was adjusted with hypotonic phosphate buffer to 
pH 7.4. For 20 min, the resultant mixture was centrifuged at 
1000 rpm. The supernatant was removed and discarded. The 
pellet was washed with phosphate buffer solution. The pellet 
containing loaded erythrocytes was stored in refrigerator 
until further characterization (Ihler, Tsang, 1987).
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Method B (Hypotonic pre-swelling)
In method B, a hypotonic solution of NaCl (0.3% 
w/v) was added to flask with erythrocytes (50% v/v). The 
RBCs were allowed to swell and 10 mL of drug solution 
(4% w/v) was then added and sonicated to facilitate the 
drug encapsulation into erythrocytes. The isotonicity of 
swelled RBCs was retained by adding 1.3% w/v NaCl 
solution and incubated at 0oC for 5 min. Then sample 
was centrifuged to remove the un-encapsulated drug. The 
supernatant was removed and discarded. The suspension 
of RBCs was washed three times with phosphate 
buffer solution at pH 7.4 to remove any free drug and 
diluted suitably with the same buffer solution. The final 
preparation was stored at 4oC in refrigerator until further 
characterization (Alpar, Irwin, 1987). 
Method C (Modified hypotonic pre-swelling)
In method C, a hypotonic solution containing NaCl 
(0.6% w/v) was added to flask with erythrocytes (50% 
v/v). The RBCs were allowed to swell and 10 mL of drug 
solution (4% w/v) was added and sonicated to facilitate 
the drug encapsulation into erythrocytes. The isotonicity 
of swelled RBCs was retained by adding NaCl solution 
(1% w/v) and incubated at 0oC for 5 min followed by 
centrifugation to remove the un- encapsulated drug. 
The suspension of RBCs was washed three times with 
phosphate buffer solution at pH 7.4 and diluted suitably 
with the same buffer solution. The final preparation was 
stored at 4oC in refrigerator until further characterization 
(Pitt et al., 1983).
Characterization of drug loaded erythrocytes
Validation of HPLC Method Used for ARM 
quantification
T h e  H P L C  m e t h o d  w a s  v a l i d a t e d  u s i n g 
International council for Harmonisation (ICH) guidelines 
for ARM quantification in different experiments. Mobile 
phase consisting of acetonitrile and deionized water 
was prepared in ratio of 93:7, respectively. The pH of 
the mobile phase was adjusted with dilute sulphuric 
acid up to 3.0. The mobile phase was used as diluent 
as well. 4 mg/mL of ARM solution was used in HPLC 
(Waters e2695) as reference standard. Nominally 4 mg/
mL of ARM obtained from drug loaded erythrocytes in 
method A, method B and method C was used as sample 
solution. Column having specifications 250-cm x 4.6-
mm; 5-µm packing L1 was used at ambient temperature 
and UV detector was set at 216 nm wave length in HPLC. 
The 20 µL injection volume was run at the flow rate of 
1.0 mL/min.
Drug loading efficiency
Drug loading efficiency in RBCs was estimated 
through a method reported earlier (Hirlekar et al., 2008). 
Briefly, 1 mL of drug loaded erythrocytes was centrifuged 
and the pellet containing loaded erythrocytes was taken for 
drug quantification. The pellet was resuspended in 1 mL 
of distilled water and heated for 20 min at 40oC followed 
by filtration through 0.22 µm filter. The Drug contents 
in filtrate were estimated by the HPLC method reported 
earlier. The drug was estimated by using the following 
equation. 
The same method was applied for quantification of 
drug loading in RBCs from other two methods.
Erythrocytes membrane integrity analysis
To distinguish between loaded and unloaded red 
blood cells and effect of different loading techniques 
on erythrocyte membrane integrity, erythrocytes 
sedimentation rate (ESR) was performed (Saulis, 
2005). Briefly, drug loaded, and normal erythrocytes 
were washed with buffer solution and were drawn in the 
WESTERGREN tube up to 0 mark with the help of rubber 
bulb and wiped out the bottom of the tube with cotton. 
The tube was set snugly upright on the WESTREGREN 
stand and made sure that there was no leakage in vertical 
position. The tube was left undisturbed for 1 hr and after 
1 hr read the results of sedimentation of the erythrocytes. 
The distance covered by erythrocytes during fall as 
well as the height of clear plasma (in millimeters) at 
the top of the column were measured for the further 
calculations.
Microscopic morphology studies of erythrocytes 
The morphology of drug loaded, and blank 
erythrocyte was studied via optical microscopy. The 
erythrocytes were washed with double distilled water 
and 10-15 µL blood was applied on glass slide to make 
a uniform smear. The smear was air dried and fixed with 
methanol (99.8%) solution and air dried again. The 
slides were stained with the commercially available 
Giemsa stain (1:9, Giemsa: distilled water). The staining 
was carried out for 15 min. After that, the slides were 
washed with the water and air dried. The margins of 
the slides were cleaned with the alcoholic swab. The 
slides were observed under microscope to observe the 
morphology of erythrocytes before and after different 
treatments.
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Drug release profile
Drug release from RBCs was estimated using 
membrane dialysis method as reported earlier (Sohail 
et al., 2016). Briefly, measured volume of ARM loaded 
RBCs was diluted in 5 mL of PBS (pH =7.4) and enclosed 
in dialysis membrane with pore size 12 KDa. The dialysis 
bag was immersed in 25 mL PBS having 1% tween 80 to 
maintain the sink condition. The system was maintained at 
37ºC with 50rpm. The samples were taken at pre-defined 
time intervals and replaced with fresh media. The samples 
were analyzed using HPLC method to estimate release 
profile from RBCs. Same method was repeated for all the 
three loading techniques. 
RESULTS AND DISCUSSION 
Erythrocytes isolation
Resealed erythrocytes have shown good potential 
to be developed as novel drug delivery system owing to 
their numerous advantages. High intracellular volume of 
erythrocytes enables the loading of high drug contents 
and provides good control over drug release. ARM 
was successfully loaded in fresh human erythrocytes 
and characterized for various parameters. Erythrocytes 
were successfully isolated from fresh human blood via 
centrifugation at 1000 rpm for 20 min. The washed 
erythrocyte pallet was suspended in isotonic buffer solution 
and stored in refrigerator till further use in different studies. 
The isolated RBCs appeared regular biconcave shape 
showing now effect on structure during isolation 
HPLC method validation
HPLC method was successfully validated for ARM 
quantification in erythrocytes following ICH guidelines 
on six basic attributes i.e. precision, linearity, range, 
specificity, accuracy, robustness. The results determined 
that all the parameters of instrument precision were well 
within the specified limits that ensured the validity of 
the developed method. The linearity of the data over a 
range of 80 to 120 µg/mL was observed and a calibration 
curve was drawn with coefficient of correlation (R2) 
0.993. This indicated that the test procedure followed the 
Beer’s law. The results of instrument specificity indicated 
the specificity obtained for ARM and placebo which 
confirmed that only standard solution gave peak of ARM at 
retention time of 5.123 min as shown in Figure 1 whereas, 
no peak was observed for placebo. The method showed 
good repeatability in terms of inter-day and intra-day 
variations confirming the precision of results. 
Drug loading 
Hypotonic treatment for drug loading is reported 
for various molecules. Three different modified hypotonic 
treatments were used to load ARM in RBCs. All the three 
methods were quite successful in loading ARM into 
erythrocytes with varying loading concentrations as shown 
in Figure 2A. These were quantified via HPLC methods 
validated for ARM. Method A was based on hypertonic 
treatment of erythrocytes resulting in shrinkage of cells 
followed by isotonic treatment. Method B and C were 
based on hypotonic treatment with varying concentration 
of NaCl solutions resulting in swelling of erythrocytes 
enabling drug loading into the cells. ARM loading was 
quantified using the developed HPLC method and was 
found to be 11.64%, 14.56% and 31.39% with method 
A, method B and method C respectively. Method A 
resulted in lowest loading efficiency as the drug crossed 
the cell membrane by diffusion method, following the 
concentration gradient and the number of pores produced 
in cell membranes was less in number to take drug 
inside the cells. Also, the loaded cells were incubated 
FIGURE 1 - (A) calibration curve of HPLC method showing linearity over a range of 80-120 µg/mL, (B) HPLC standard 
chromatogram showing retention peak of artemether at 5.123 min.
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at 40oC for drug analysis, the drug might be degraded, 
and chromatograph results showed low amount of drug 
encapsulation.
The lower loading efficiency with method B was 
again resulted because of the incubation of the cells at 
0-4oC which solidified the cell membrane fatty acids and 
resisted the cellular lysis during drug loading and prior 
to the treatment of erythrocytes with hypotonic solution. 
The hypotonic salt solution produced low number of 
pores in cell membrane because of swelling of the cells 
due to hydrostatic pressure inside the cells which was 
created by the osmotic movement of the water molecules 
across the membrane. Those pores facilitated the entry 
of drug molecules inside the cells and enhanced the drug 
encapsulation efficiency that was 14.56%. The other 
possible reason might be the lysis of the cells in 0.3% 
NaCl solution and incubation at 40oC for drug analysis 
which affected the drug stability and premature release 
from erythrocyte destruction. Method C resulted in highest 
drug loading of 31.39%. This might attribute a number 
of factors like the increased refrigeration of erythrocytes 
at 0-4oC, prior to hypotonic treatment, resulted in more 
solidification of the cell membrane components thus 
prevented the cellular lysis. The loading of ARM drug into 
erythrocytes was low as compared to ARM following same 
method C, this might be due to higher molecular weight 
and differences in other parameters such as incubation 
period and incubation temperature of erythrocytes. 
Moreover, the cell lysis in method B and C was prevented 
by treating the cells with 0.6% NaCl solution. Which 
caused opening of cellular pores and less cellular lysis.
ESR analysis
Erythrocyte sedimentation rate (ESR) is a simple and 
inexpensive laboratory test to access acute phase response. 
It is the estimation of suspending stability of RBCs and 
is relate to number and size of RBCs and to relative 
concentration of plasma proteins. The effect of three 
treatments on RBCs membrane integrity was estimated 
via erythrocyte sedimentation rate (ESR) analysis. The 
sedimentation rate for loaded and unloaded erythrocytes 
have been shown in Figure 2B. The result showed normal 
ESR of untreated RBCs as compared to drug loaded 
RBCs. The values of ESR for drug loaded erythrocytes 
were observed to be 51 mm/h, 63 mm/h and 90 mm/h for 
method A, method B and Method C respectively. The ESR 
value of drug loaded erythrocytes was higher than normal 
ESR value (0-15 mm/h) erythrocytes because of increase 
in the mass of red blood cells due to drug loading. As the 
maximum drug loading into erythrocytes was achieved 
in method C that’s why the ESR value in the erythrocytes 
of method C was greater than all the other erythrocytes 
obtained from all other drug loading methods.
Drug release studies
Once successfully encapsulated, the drug must come 
out of the carrier to produce desired effect. A number 
of mechanism are suggested by which drug is released 
from resealed erythrocytes. Post hypotonic treatment 
may result in decreasing membrane integrity because of 
pore formation (Pribush, Meyerstein, Meyerstein, 2002). 
During circulation, they are readily taken up by RES and 
other stress mechanisms which degrade them to release 
drug. Drug release from ARM loaded RBCs was evaluated 
for 8 hours using PBS having pH = 7.4 as medium via 
membrane dialysis method. The results obtained are 
shown in Figure 3 indicating percentage drug release 
at various time intervals. RBCs produced from method 
C showed maximum release (above 85%) within 4 h as 
compared to Method B which showed around 80% release 
FIGURE 2 - (A) Drug loading efficiency of 3 different method used for erythrocytes. (B) effect of different loading techniques on 
ESR showing integrity of membrane. The results are presented as Mean ±SD of three experiments.
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in same time. Method A showed better release profile as 
only 65% of the encapsulated drug was released in 4 h. 
Furthermore, these RBCs showed gradual release of ARM 
from the loaded cells as the treatment followed by method 
A might have caused less damage to the cell membrane 
and drug retained for longer period of time with survival 
of cells for longer period. Also, the possible reason behind 
less control on drug release by method B and C suggests 
the involvement of membrane integrity and amount of 
drug loaded inside the RBCs. The higher loaded amount 
along with high treatment variables affected the membrane 
integrity more as compared to low drug loading. 
Microscopic evaluation of cell morphology
The change in erythrocyte morphology after 
successful drug encapsulation was assessed by microscopic 
examination of stained erythrocytes. Both drug loaded 
(Method A) and normal erythrocytes were examined 
at 100 x resolution to observe the differences and are 
shown in Figure 4a & 4b. The drug loaded cell appeared 
much increased in size as compared to normal cells when 
observed at same magnification. The hollow central 
compartment seen in normal cells, was disappeared in 
drug loaded cells, suggesting the encapsulation of drug 
in intracellular space. Moreover, the membrane appeared 
a bit rough and irregular shape in appearance after 
hypotonic treatment compared to the smooth and spherical 
appearance of erythrocytes in normal sample.
CONCLUSIONS
Drug loaded erythrocytes are the safe and effective 
for sustained drug delivery as this novel system has 
is biocompatible. Moreover, targeting to the organ of 
the reticule-endothelial system is possible with loaded 
FIGURE 3 - In-vitro release of artemether from erythrocytes followed by three different loading techniques. The results are presented 
as Mean ±SD of three experiments.
FIGURE 4 - Giemsa stained RBCs (A) Normal (B) Drug loaded showing changes in morphology before and after drug loading 
techniques.
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erythrocytes. The loading of antimalarial drug in 
erythrocytes will follow the targeted missile technology for 
plasmodium present in blood stream. The lipophilic drugs 
cannot be administered intravenously, due to requirement 
of large volume of vehicle, but this erythrocyte based drug 
delivery system will make it quite possible. The hypotonic 
treatment showed good drug loading for lipophilic drugs 
with an improved membrane integrity and drug release 
over a longer period of time. This could be helpful in 
designing relatively more stable formulation. Overall, 
the study suggested that these RBCs possess potential to 
be taken up further in designing an efficient drug delivery 
system for lipophilic drug molecules. 
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